普洛药业(000739) - 2014 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2014 was ¥989,582,252.30, representing a 15.9% increase compared to ¥853,842,243.05 in the same period last year[8] - Net profit attributable to shareholders reached ¥129,291,577.63, a significant increase of 465.94% from ¥22,845,283.08 year-on-year[8] - The net profit after deducting non-recurring gains and losses was ¥50,491,439.94, up 141.46% from ¥20,910,935.83 in the previous year[8] - The basic earnings per share increased to ¥0.16, reflecting a growth of 166.67% compared to ¥0.06 in the same period last year[8] - The weighted average return on equity rose to 6.96%, an increase of 5.44 percentage points from 1.52% year-on-year[8] - Total profit and net profit increased by 348.45% and 483.55% respectively compared to the same period last year, driven by increased product gross profit and investment income from the disposal of Shanghai Pharmaceutical Research Institute[16] Assets and Shareholder Equity - Total assets at the end of the reporting period were ¥4,644,499,479.69, a slight decrease of 0.38% from ¥4,662,256,191.02 at the end of the previous year[8] - The net assets attributable to shareholders increased by 7.21% to ¥1,921,631,192.33 from ¥1,792,339,614.71 at the end of the previous year[8] - The number of shareholders at the end of the reporting period was 43,022, with the top ten shareholders holding significant stakes[11] Income and Expenses - Other business income increased by 36.70% compared to the previous year, primarily due to increased income from waste disposal[15] - Management expenses rose by 30.25% year-on-year, driven by rapid growth in R&D investment and increased costs related to labor, depreciation, and amortization[15] - Financial expenses decreased by 46.04% compared to the same period last year, mainly due to increased exchange gains[16] - Investment income increased by 100% compared to the same period last year, attributed to the disposal of the investment in Shanghai Pharmaceutical Research Institute[16] - Operating profit increased by 382.19% compared to the same period last year, primarily due to increased product gross profit and the investment income from the disposal of Shanghai Pharmaceutical Research Institute[16] Cash Flow - Cash received from tax refunds increased by 37.43% compared to the same period last year, mainly due to an increase in receivable export tax refunds[17] - Cash inflow from investment activities increased by 489 times compared to the same period last year, primarily due to increased cash recovered from investments[17] - Cash flow from financing activities decreased by 50.95% compared to the same period last year, mainly due to no cash received from new share issuance this period[17] - Net cash increase in cash and cash equivalents decreased by 60.08% compared to the same period last year, primarily due to last year's capital increase of 283 million and higher repayment amounts this year[18]